A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Inclusion Criteria

• •Adults 18 years or older
• •First advanced of diagnosis of metastatic/Stage IV) melanoma
• •Tested for PD-L1 expression with a tumor proportion score (TPS) greater than or equal to 1% (Phase 1 data collection)
• •Initiating a first line of therapy during the index period between October 1, 2015 through July 1, 2017
• •Medical history available for medical chart abstraction from date of diagnosis through most recent or current therapy (defined as end of data collection period)